VTIX is trading 5% up at approximately $3.51 in pre-market action after announcing a collaboration with Rutgers University to develop AI-assisted VR therapy for neurodivergent children.
- The partnership utilizes Virtuix’s Omni One platform, establishing a significant new healthcare-focused use case for the company's VR hardware and AI capabilities.
- The announcement has sparked renewed investor interest, allowing the stock to gain momentum despite broader market weakness and recent volatility in major indices.